Why Electra Therapeutics, Inc.’s (ETRA) Stock Is Down 11.92%
As of Thursday, November 05, Electra Therapeutics, Inc.’s ETRA share price has dipped by 11.92%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Electra Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company develops therapies that targets signal regulatory proteins for the treatment of novel targets for treatment of immune-mediated diseases and cancer. Its lead product candidate is ipsoprubart, that targets signal regulatory protein on the cell surface of myeloid and T cells and depletes pathological immune cells, treatment for secondary hemophagocytic lymphohistiocytosis and T/NK Cell Malignancies; ELA822, a novel SIRP-specific monoclonal antibody for deplete activated T cells, treatment for T cell mediated immune disorders. Electra Therapeutics, Inc. was incorporated in 2018 and is based in South San Francisco, California.
Commentary & Analysis
Why Electra Therapeutics, Inc.’s (ETRA) Stock Is Down 8.36%
As of Wednesday, November 04, Electra Therapeutics, Inc.’s ETRA share price has dipped by 8.36%, which has investors questioning if this is right time to buy.Tudor Pop
Why Electra Therapeutics, Inc.’s (ETRA) Stock Is Up 5.88%
As of Tuesday, November 03, Electra Therapeutics, Inc.’s ETRA share price has surged by 5.88%, which has investors questioning if this is right time to sell.Michael Rose
Why Electra Therapeutics, Inc.’s (ETRA) Stock Is Down 5.74%
As of Monday, November 02, Electra Therapeutics, Inc.’s ETRA share price has dipped by 5.74%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Electra Therapeutics, Inc.’s (ETRA) Stock Is Up 5.63%
As of Wednesday, October 28, Electra Therapeutics, Inc.’s ETRA share price has surged by 5.63%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | ETRA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $500.3 | $227.3 | 38% |
|
| Shares Out (Mil) | 0.0 | 53.4 | 0% |
|
| Institutional Ownership | 48.5% | 92.9% | 22% |
|
| Float (Mil) | 29.9 | 41.4 | 36% |
|
| Beta | na | 0.95 | na |
|
| Avg Daily Volume (000s) | 292 | 468 | 50% |
|
| Price Change (52-week) |
na | 47.4% | na |
|
| Growth | ETRA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | ETRA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($86) | ($44) | 12% |
|
| EPS (TTM) | na | ($1.600) | na |
|
| Operating Cash Flow (TTM) (Mil) | ($75) | ($34) | 7% |
|
| Net Cash Flow (TTM) (Mil) | $50 | $1 | 70% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $4 | 18% |
|
| Enterprise Value (Q1) (Mil) | $1,047 | $174 | 41% |
|
| Valuation | ETRA | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.14 | na |
|
| P/E | na | 20.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | ETRA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.5% | na |
|
| Net Margin | na | (69.8%) | na |
|
| ROA | (160.6%) | (47.1%) | 3% |
|
| ROE | 77.9% | (52.0%) | 95% |
|
| Liabilities to Assets | 13.9% | 29.7% | 9% |
|
| F-Score | 1 | 2 | na |
|
Electra Therapeutics, Inc. did not pass any screens on 11/4/2026.
